Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring

John A. Moss, Amanda M. Malone, Thomas J. Smith, Sean Kennedy, Etana Kopin, Cali Nguyen, Josh Gilman, Irina Butkyavichene, Kathleen Vincent, Massoud Motamedi, David R. Friend, Meredith R. Clark, Marc M. Baum

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Vaginal microbicides may play an important role in protecting women from HIV infection. A strong synergy between HSV and HIV has been observed, and epidemiological studies demonstrate that HSV infection increases the risk of HIV acquisition. Incorporation of the antiretroviral tenofovir (TFV) along with the antiherpetic acyclovir (ACV) into combination intravaginal rings (IVRs) for sustained mucosal delivery of both compounds could lead to increased microbicide product adherence and efficacy compared with conventional vaginal formulations. A novel, dual-protection "pod IVR" platform developed in-house and delivering ACV and TFV was evaluated in rabbit and sheep models. The devices were safe and exhibited sustained release of both drugs independently and at controlled rates over the 28-day studies. Daily release rates were estimated based on residual drug content of the used devices: rabbits, 343±335μg day-1 (ACV) and 321±207μg day-1 (TFV); sheep, 174±14μg day-1 (ACV) and 185±34μg day -1 (TFV). Mean drug levels in sheep vaginal samples were as follows: secretions, 5.25±7.31μg ml-1 (ACV) and 20.6±16. 2μg ml-1 (TFV); cervicovaginal lavage fluid, 118±113 ng ml-1 (ACV) and 191±125 ng ml-1 (TFV); tissue, 173 ng g-1 (ACV) and 93 ng g-1 (TFV). An in vitro-in vivo correlation was established for both drugs and will allow the development of future formulations delivering target levels for prophylaxis and therapy. These data suggest that the IVR based on the pod design has potential in the prevention of transmission of HIV-1 and other sexually transmitted pathogens.

Original languageEnglish (US)
Pages (from-to)875-882
Number of pages8
JournalAntimicrobial Agents and Chemotherapy
Volume56
Issue number2
DOIs
StatePublished - Feb 2012

Fingerprint

Tenofovir
Acyclovir
Sheep
Anti-Infective Agents
HIV
Pharmaceutical Preparations
Rabbits
Equipment and Supplies
Therapeutic Irrigation
HIV Infections
HIV-1
Epidemiologic Studies

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Moss, J. A., Malone, A. M., Smith, T. J., Kennedy, S., Kopin, E., Nguyen, C., ... Baum, M. M. (2012). Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring. Antimicrobial Agents and Chemotherapy, 56(2), 875-882. https://doi.org/10.1128/AAC.05662-11

Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring. / Moss, John A.; Malone, Amanda M.; Smith, Thomas J.; Kennedy, Sean; Kopin, Etana; Nguyen, Cali; Gilman, Josh; Butkyavichene, Irina; Vincent, Kathleen; Motamedi, Massoud; Friend, David R.; Clark, Meredith R.; Baum, Marc M.

In: Antimicrobial Agents and Chemotherapy, Vol. 56, No. 2, 02.2012, p. 875-882.

Research output: Contribution to journalArticle

Moss, JA, Malone, AM, Smith, TJ, Kennedy, S, Kopin, E, Nguyen, C, Gilman, J, Butkyavichene, I, Vincent, K, Motamedi, M, Friend, DR, Clark, MR & Baum, MM 2012, 'Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring', Antimicrobial Agents and Chemotherapy, vol. 56, no. 2, pp. 875-882. https://doi.org/10.1128/AAC.05662-11
Moss, John A. ; Malone, Amanda M. ; Smith, Thomas J. ; Kennedy, Sean ; Kopin, Etana ; Nguyen, Cali ; Gilman, Josh ; Butkyavichene, Irina ; Vincent, Kathleen ; Motamedi, Massoud ; Friend, David R. ; Clark, Meredith R. ; Baum, Marc M. / Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring. In: Antimicrobial Agents and Chemotherapy. 2012 ; Vol. 56, No. 2. pp. 875-882.
@article{64f64e26715b4d8cbe1259e86df5cd51,
title = "Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring",
abstract = "Vaginal microbicides may play an important role in protecting women from HIV infection. A strong synergy between HSV and HIV has been observed, and epidemiological studies demonstrate that HSV infection increases the risk of HIV acquisition. Incorporation of the antiretroviral tenofovir (TFV) along with the antiherpetic acyclovir (ACV) into combination intravaginal rings (IVRs) for sustained mucosal delivery of both compounds could lead to increased microbicide product adherence and efficacy compared with conventional vaginal formulations. A novel, dual-protection {"}pod IVR{"} platform developed in-house and delivering ACV and TFV was evaluated in rabbit and sheep models. The devices were safe and exhibited sustained release of both drugs independently and at controlled rates over the 28-day studies. Daily release rates were estimated based on residual drug content of the used devices: rabbits, 343±335μg day-1 (ACV) and 321±207μg day-1 (TFV); sheep, 174±14μg day-1 (ACV) and 185±34μg day -1 (TFV). Mean drug levels in sheep vaginal samples were as follows: secretions, 5.25±7.31μg ml-1 (ACV) and 20.6±16. 2μg ml-1 (TFV); cervicovaginal lavage fluid, 118±113 ng ml-1 (ACV) and 191±125 ng ml-1 (TFV); tissue, 173 ng g-1 (ACV) and 93 ng g-1 (TFV). An in vitro-in vivo correlation was established for both drugs and will allow the development of future formulations delivering target levels for prophylaxis and therapy. These data suggest that the IVR based on the pod design has potential in the prevention of transmission of HIV-1 and other sexually transmitted pathogens.",
author = "Moss, {John A.} and Malone, {Amanda M.} and Smith, {Thomas J.} and Sean Kennedy and Etana Kopin and Cali Nguyen and Josh Gilman and Irina Butkyavichene and Kathleen Vincent and Massoud Motamedi and Friend, {David R.} and Clark, {Meredith R.} and Baum, {Marc M.}",
year = "2012",
month = "2",
doi = "10.1128/AAC.05662-11",
language = "English (US)",
volume = "56",
pages = "875--882",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "2",

}

TY - JOUR

T1 - Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring

AU - Moss, John A.

AU - Malone, Amanda M.

AU - Smith, Thomas J.

AU - Kennedy, Sean

AU - Kopin, Etana

AU - Nguyen, Cali

AU - Gilman, Josh

AU - Butkyavichene, Irina

AU - Vincent, Kathleen

AU - Motamedi, Massoud

AU - Friend, David R.

AU - Clark, Meredith R.

AU - Baum, Marc M.

PY - 2012/2

Y1 - 2012/2

N2 - Vaginal microbicides may play an important role in protecting women from HIV infection. A strong synergy between HSV and HIV has been observed, and epidemiological studies demonstrate that HSV infection increases the risk of HIV acquisition. Incorporation of the antiretroviral tenofovir (TFV) along with the antiherpetic acyclovir (ACV) into combination intravaginal rings (IVRs) for sustained mucosal delivery of both compounds could lead to increased microbicide product adherence and efficacy compared with conventional vaginal formulations. A novel, dual-protection "pod IVR" platform developed in-house and delivering ACV and TFV was evaluated in rabbit and sheep models. The devices were safe and exhibited sustained release of both drugs independently and at controlled rates over the 28-day studies. Daily release rates were estimated based on residual drug content of the used devices: rabbits, 343±335μg day-1 (ACV) and 321±207μg day-1 (TFV); sheep, 174±14μg day-1 (ACV) and 185±34μg day -1 (TFV). Mean drug levels in sheep vaginal samples were as follows: secretions, 5.25±7.31μg ml-1 (ACV) and 20.6±16. 2μg ml-1 (TFV); cervicovaginal lavage fluid, 118±113 ng ml-1 (ACV) and 191±125 ng ml-1 (TFV); tissue, 173 ng g-1 (ACV) and 93 ng g-1 (TFV). An in vitro-in vivo correlation was established for both drugs and will allow the development of future formulations delivering target levels for prophylaxis and therapy. These data suggest that the IVR based on the pod design has potential in the prevention of transmission of HIV-1 and other sexually transmitted pathogens.

AB - Vaginal microbicides may play an important role in protecting women from HIV infection. A strong synergy between HSV and HIV has been observed, and epidemiological studies demonstrate that HSV infection increases the risk of HIV acquisition. Incorporation of the antiretroviral tenofovir (TFV) along with the antiherpetic acyclovir (ACV) into combination intravaginal rings (IVRs) for sustained mucosal delivery of both compounds could lead to increased microbicide product adherence and efficacy compared with conventional vaginal formulations. A novel, dual-protection "pod IVR" platform developed in-house and delivering ACV and TFV was evaluated in rabbit and sheep models. The devices were safe and exhibited sustained release of both drugs independently and at controlled rates over the 28-day studies. Daily release rates were estimated based on residual drug content of the used devices: rabbits, 343±335μg day-1 (ACV) and 321±207μg day-1 (TFV); sheep, 174±14μg day-1 (ACV) and 185±34μg day -1 (TFV). Mean drug levels in sheep vaginal samples were as follows: secretions, 5.25±7.31μg ml-1 (ACV) and 20.6±16. 2μg ml-1 (TFV); cervicovaginal lavage fluid, 118±113 ng ml-1 (ACV) and 191±125 ng ml-1 (TFV); tissue, 173 ng g-1 (ACV) and 93 ng g-1 (TFV). An in vitro-in vivo correlation was established for both drugs and will allow the development of future formulations delivering target levels for prophylaxis and therapy. These data suggest that the IVR based on the pod design has potential in the prevention of transmission of HIV-1 and other sexually transmitted pathogens.

UR - http://www.scopus.com/inward/record.url?scp=84856071435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856071435&partnerID=8YFLogxK

U2 - 10.1128/AAC.05662-11

DO - 10.1128/AAC.05662-11

M3 - Article

VL - 56

SP - 875

EP - 882

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 2

ER -